BiotechTube

WVE-210201 (suvodirsen) + Placebo

Phase 2/3Terminated
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Trial Timeline

Sep 4, 2019 → Jan 9, 2020

NCT ID
NCT03907072

About WVE-210201 (suvodirsen) + Placebo

WVE-210201 (suvodirsen) + Placebo is a phase 2/3 stage product being developed by WaVe Life Sciences for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03907072. Target conditions include Duchenne Muscular Dystrophy.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT03907072Phase 2/3Terminated

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from WaVe Life Sciences

WVE-N531Phase 2
47
WVE-N531Phase 1/2
36
WVE-120102 + PlaceboPhase 1/2
36
SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + SAD: Pooled Placebo + MD: 30mg WVE-003 + MD: PlaceboPhase 1/2
36
WVE-006Phase 1/2
36